Synchron raises $200M to advance its brain-computer interface for paralysis

Synchron Raises $200M to Advance Brain-Computer Interface for Paralysis

Synchron has secured $200 million in a Series D funding round. The company plans to use these funds to expand operations and speed up the commercialization of its non-surgical brain-computer interface (BCI) designed for people living with paralysis.

Funding Details

The round was led by Double Point Ventures and included participation from Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, and Metis. Additional investors included the Australian National Reconstruction Fund, T.Rx Capital, the Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.

Industry Momentum

With this round, the New York-based medtech company has raised a total of $345 million. The investment reflects growing momentum in the BCI sector as companies race to develop technologies aimed at restoring function and communication for patients with paralysis.

Recent Developments in BCI

Earlier this week, Precision Neuroscience announced a new partnership with SCI Ventures, backed by the Christopher & Dana Reeve Foundation, to advance its Layer 7 Cortical Interface. In related research, Science Corp.’s PRIMA BCI retinal implant recently demonstrated restored partial vision in individuals affected by severe age-related macular degeneration.

“The funding marks a pivotal moment for Synchron and the wider brain-computer interface field as innovation moves closer to real-world application,” the company stated.

Author’s Summary

Synchron’s $200M Series D round positions the company as a frontrunner in developing non-surgical brain-computer interfaces to help people with paralysis regain communication and control.

more

Fierce Biotech Fierce Biotech — 2025-11-07

More News